DEAN, SCHOOL OF PHARMACY
Prof. Kwasi Adomako Ohemeng was appointed by the University Council as the Acting Dean of the School of Pharmacy. The appointment took effect from April 1, 2017. Until this appointment, he was the Head of the Department of Pharmaceutical Science of the University.
Professor Ohemeng graduated with a B.Pharm Honours degree from the Kwame Nkrumah University of Science and Technology (KNUST) in 1978. He also served as teaching assistant at the Pharmaceutical Chemistry Department in 1979 to 1980. He then proceeded to Duquesne University Pittsburgh, Pennsylvania where he obtained his Ph.D (Medicinal Chemistry) in 1984. Whilst at Duquesne, he was awarded the Duquesne University Faculty Development Fellowship and also served as Teaching/Research Assistant in the Medicinal Chemistry department. Upon completion, he was awarded the Burroughs-Wellcome fellowship from 1984 to 1987 to undertake a post-doctoral appointment in the Chemistry Department, University of North Carolina, Chapel Hill, NC. USA
Prof. Ohemeng is a leading academic with considerable expertise in pharmaceutical research, university teaching, academic writing, with vast institutional management experience and close association with a number of international pharmaceutical entities. He has over 30 years of experience working with several major drug manufacturers in the United States, rising to the position of Principal Pharmaceutical Scientist, at Johnson & Johnson. Then to a group leader at Bristol Myers and Squibb. Before moving to Ghana, he was the Executive Director of Medicinal Chemistry, Paratek Pharmaceuticals, Boston Ma USA
He has participated in various U.S and International conferences in the industry and has a great deal of familiarity with the various aspects of the drug development/manufacturing business including current research and development activities. He has up-to-date information on current research and development activities with more than fifty patents and over eighty-five publications and presentations to his credit. He was in charge of developing three new drugs for Immtech International and Paratek Pharmaceuticals. Both Omadacycline and Sarecycline are in phase 3 clinical development in the USA.
He has been a member of a number of boards, committees and teams, included but not limited to the following: Central University SAS Faculty Board, SAS Strategic Plan Implementation Committee, Ghana Pharmacy Council Oral Exams Committee, United States NIH RO29 Grants Reviewer
He has also served as a reviewer for several peer reviewed Medicinal Chemistry Journals, such as Bioorganic and Medicinal Chemistry Letters, Bioorganic and Medicinal Chemistry, Journal of Medicinal Chemistry and on the Editorial Board of Emerging Drugs.
Prof Ohemeng also has professional affiliations with the America Chemical Society (Divisions of Organic and Medicinal Chemistry), American Association for the Advancement of Science and the Ghana Pharmaceutical Society.